Tonazocine Explained

Tonazocine (WIN-42,156) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials for the treatment of postoperative pain,^[1] but development was apparently ceased and ultimately it was never marketed. Tonazocine is a partial agonist at both the mu-opioid and delta-opioid receptors, but acting more like an antagonist at the former and more like an agonist at the latter.^{[2] [3]} It lacks most of the side effects of other opioids such as adverse effects on the cardiovascular system and respiratory depression, but it can cause sedation (although to a lesser degree of typical opioids), and in some patients it may induce hallucinations (probably via binding to and activating the κ-opioid receptor).^[4]

See also

• Zenazocine

Notes and References

1. Book: American Chemical Society. Division of Medicinal Chemistry . Annual Reports in Medicinal Chemistry . 30 November 2011 . 1990 . Academic Press . 978-0-12-040525-1 . 12.
2. Ward SJ, Pierson AK, Michne WF . Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964) . Neuropeptides . 5 . 4–6 . 375–8 . February 1985 . 2860595 . 10.1016/0143-4179(85)90032-0. 20674308 .
3. Hudzik TJ, Howell A, Payza K, Cross AJ . Antiparkinson potential of delta-opioid receptor agonists . European Journal of Pharmacology . 396 . 2–3 . 101–7 . May 2000 . 10822062 . 10.1016/S0014-2999(00)00209-0.
4. Book: Aronson, Jeffrey K. . Jeffrey Aronson . Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs . 30 November 2011 . 30 November 2009 . Elsevier . 978-0-444-53273-2 . 154.